Site Editor

Thomas Flaig, MD


Chinese Research Team Identifies Potential Biomarker of Early-Stage Bladder Cancer

By: Celeste L. Dixon
Posted: Friday, December 2, 2022

The quest to identify reliable biomarkers associated with early-stage bladder cancer “is of great importance to early treatment and an improved outcome,” according to a team of researchers that has done preliminary work to advance this goal. In BMC Urology, Conghui Han, MD, of Xuzhou Medical University, China, and colleagues described their finding that CDH1 overexpression seems to indicate early-stage disease, and that it also is inversely correlated with immune infiltration.

Theoretically, CDH1 overexpression and other oncogenic alterations uncovered by the investigators may prove to be novel biomarkers, potentially serving to diagnose early-stage bladder cancer and help create personalized therapeutic targets, but they must be confirmed experimentally, the team emphasized. Among the research tools used by the investigators were the MethSurv database, the Cancer Cell Line Encyclopedia database, and data of The Cancer Genome Atlas.

In their analysis of CDH1 specifically, they found that “six methylated sites indicated a good prognosis, and one site indicated an aberrant prognosis…. High CDH1 expression was negatively correlated with infiltrations by most immune cells, such as plasmacytoid dendritic cells, regulatory T cells, macrophages, neutrophils, dendritic cells, and natural killer cells.” Further, explained the team, CDH1 was highly positively correlated with EPCAM and appeared to be directly regulated by miR-383. Separately, IGFBP3, PPARG, SDC1, EPCAM, ACTA2, COL3A1, TPM1, ACTC1, and ACTN1 were found to be “vital players” in the progression of early-stage bladder cancer, according to the study authors.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.